Isto and Arteriocyte join forces to form leading biologics player, Isto Biologics
The integration of Isto Technologies and Arteriocyte Medical Systems will expand best-in-class product portfolios and build upon both companies’ deep scientific expertise in biologics and cell therapy to provide better patient outcomes
ST. LOUIS, Oct. 19, 2016
ST. LOUIS, Oct. 19, 2016 /PRNewswire/ — Isto Holdings, the parent company of St. Louis-based Isto Technologies – a leader in bone-regeneration technologies and cell-based therapy – has acquired medical-device company Arteriocyte Medical Systems Inc. of Hopkinton, Massachusetts, with plans to integrate the companies under the name Isto Biologics. Isto Biologics will be focused on offering evidence-based solutions to expand its spine, orthopedics, and functional-medicine product portfolios. Isto Biologics will be headquartered in St. Louis, while maintaining operations in Massachusetts.
“We’re excited to bring together two great organizations under the Isto umbrella and build upon their leading biologics platforms,” said Anthony Chambers, Director at Thompson Street Capital Partners, which provided capital for the transaction. “Both Isto and Arteriocyte have achieved remarkable success by developing innovative, clinically-proven product offerings that help improve patient outcomes. The integrated product portfolio, combined with the expanded sales force and broader distribution network, will allow Isto Biologics to extend its reach within the spine, orthopedics, and functional-medicine markets.”
George Dunbar, current CEO of Isto Technologies, will serve as CEO of Isto Biologics. “We are grateful for the support of Thompson Street Capital Partners and excited to lead Isto Biologics into the future,” said Mr. Dunbar. “The integration of Isto and Arteriocyte presents an opportunity to leverage our combined expertise to establish a strong position in an ever-changing market and better serve our physician partners, as they work to grow their practice and meet the demands of value-based healthcare.”
Isto Biologics’ expanded, best-in-class product portfolio will feature Arteriocyte’s market-leading MAGELLAN Autologous Platelet Separator and Isto’s bone-growth and cell-therapy products, including InQu Bone Graft Extender & Substitute; Influx, a natural bone-graft material; and CellPoint, a concentrated bone marrow aspirate system.
About Isto Biologics
Isto Biologics was formed in 2016 when St. Louis-based Isto Technologies and Arteriocyte Medical Systems Inc. of Hopkinton, Massachusetts, integrated under the Isto Holdings umbrella. Isto Biologics is focused on offering evidence-based solutions for bone regeneration and cell therapy to help improve patient outcomes. The company’s best-in-class product offerings include Arteriocyte’s market-leading MAGELLAN Autologous Platelet Separator and Isto’s bone-growth and cell-therapy products including InQu Bone Graft Extender & Substitute; Influx, a natural bone-graft material; and CellPoint, a concentrated bone marrow aspirate system.
For more information, visit istobiologics.com.
Director of Marketing
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/isto-and-arteriocyte-join-forces-to-form-leading-biologics-player-isto-biologics-300347724.html
SOURCE Isto Biologics